Cancer prevalence in a metropolitan HIV clinic

Abstract

IntroductionMorbidity and mortality rates from AIDs defining cancers have fallen significantly since the introduction of highly active antiretroviral therapy (HAART). Patients are now living longer with HIV and are at a greater risk of other HIV- and non-HIV related malignancies. We report what we believe to be the first UK cancer prevalence study in the modern HAART era.MethodsA retrospective review of electronic clinic letters was performed for all patients currently receiving, and those who had died whilst receiving, their HIV care at our centre. Demographics of patients with pre-cancerous changes, an active or previous cancer were recorded.ResultsThere were 438 active patients (369 male, 69 female) and 18 deceased patients (12 male, 6 female) in April 2014. Thirty-six out of four hundred fifty-six (8%) cancer diagnoses were found overall. Thirty-one out of four hundred thirty-eight (7%) diagnoses in active patients and 5/18 (28%) in deceased patients. More than half of those diagnosed with cancer were aged 50 or over (17/31 [55%]). In active patients 17/31 (55%) were AIDs defining cancers, with the most common type of cancer diagnosis overall being Kaposi's sarcoma (12/31 [39%]). There were 5/31 (16%) cases of non-Hodgkin's lymphoma. The most common non-AIDs defining cancer was basal cell carcinoma of which there were 5/31 (16%) cases, followed by squamous cell carcinoma (3/31 [10%]) and testicular cancer (3/31 [10%]). Other cancers included colorectal (2/31 [6%]) and prostate cancer (1/31 [3%]). In all five deceased patients, cancer was the cause of death. There were four acute presentations with an aggressive glioma, Burkitt's lymphoma, an undiagnosed primary lung malignancy and a late diagnosed cervical cancer. The fifth patient died following the recurrence of a transitional cell cancer of the bladder after an initial diagnosis of seven years earlier. Eighteen out of sixty-nine (26%) of females were found to have at least mild dyskariosis on cervical screening. Anal intraepithelial neoplasia was diagnosed in 4/438 (1%) of patients.ConclusionsNon-AIDS defining malignancies account for almost half of the cancers in our cohort. This number may rise further as patients live longer with HIV. Good communication between oncologists and HIV physicians is paramount to manage the complex interactions of HIV and cancer, increase HIV testing in cancer services and address cancer risk factors in existing HIV patients.

HIV-1-infected cell-derived exosomes promote the growth and progression of cervical cancer

“…Women infected with HIV are more likely to have aggressive cervical cancer, and those with HIV infection at the time of consultation are often more serious cases than those without HIV infection [1][2][3][4][5] . Compared with that of non-HIV-infected women, the infection rate of HPV in the reproductive tract of HIV-infected women is also significantly higher.…”

Human Immunodeficiency Virus in Adults Undergoing Surgery for Brain Tumors

“…Since its discovery in the 1980s, HIV has increasingly become a chronic condition with a life expectancy similar to the general population due to the advent of therapy with HAART [ 5 ]. Most of the existing literature on HIV and brain tumors focus on tumor prevalence in HIV-positive populations rather than the HIV prevalence in tumor patients [ 6 , 7 ]. The use of HAART has dramatically added to the longevity of HIV-positive, seronegative patients, who are now living long enough to develop a range of cancers thought to arise in part due to reduced immune surveillance, direct effects of HIV, or oncogenic viral infection.…”

HIV-Associated Urogenital Malignancies

“…T1c (3) T2a (4) T2b (1) pT2c (8) 16 (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22) 8 (100) 634 (506-980) < 50 (8) RALP (8) PSA T1c (6) T2b (5) T2c (3) n.a.…”